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Abstract Endothelin-1 (ET-1) is a potent endogenous
vasoconstrictor, mainly secreted by endothelial cells. It acts
through two types of receptors: ETA and ETB. Apart from
a vasoconstrictive action, ET-1 causes fibrosis of the vas-
cular cells and stimulates production of reactive oxygen
species. It is claimed that ET-1 induces proinflammatory
mechanisms, increasing superoxide anion production and
cytokine secretion. A recent study has shown that ET-1 is
involved in the activation of transcription factors such as
NF-jB and expression of proinflammatory cytokines
including TNF-a, IL-1, and IL-6. It has been also indicated
that during endotoxaemia, the plasma level of ET-1 is
increased in various animal species. Some authors indicate
a clear correlation between endothelin plasma level and
morbidity/mortality rate in septic patients. These patho-
logical effects of ET-1 may be abrogated at least partly by
endothelin receptor blockade. ET-1 receptor antagonists
may be useful for prevention of various vascular diseases.
This review summarises the current knowledge regarding
endothelin receptor antagonists and the role of ET-1 in
sepsis and inflammation.
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Pathogenesis of Sepsis
Sepsis is defined as a systemic inflammatory response
syndrome, most commonly provoked by severe bacterial
infection (Naito et al. 2014; Sagy et al. 2013; Zhang et al.
2014) This critical condition, with a mortality rate of about
50–80 %, is characterised by hyperthermia or hypothermia,
tachypnea, tachycardia, leucocytosis or leucopenia, with
immature neutrophils, and organ dysfunction due to
impaired tissue perfusion (Sagy et al. 2013). Endotoxic
shock is also associated with pulmonary hypertension,
systemic hypotension and cardiac dysfunction (Forni et al.
2005). The mechanisms underlying the pathogenic effects
of sepsis are still not completely understood.
The primary cause of escalated inflammatory response
in septic shock is the presence of bacterial toxins. These
include the lipopolysaccharide (LPS) endotoxin, which is a
compound of a Gram-negative bacterial cell wall and an
exotoxin (superantigen) from Gram-positive bacteria.
When released into the blood, these bacterial products
induce macrophages to secrete large amounts of inflam-
matory cytokines like tumour necrosis factor (TNF)-a,
interleukin (IL)-1, IL-6, and IL-8, by the activation of
signalling cascades such as nuclear factor (NF)-jB and
mitogen-activated protein kinase (MAPKs) pathways.
Exotoxins also activate T-lymphocytes to produce proin-
flammatory mediators, IL-2 and interferon c, which
stimulate inducible nitric oxide synthase (iNOS) to produce
nitric oxide (NO). Together with IL-2, they also intensify
the release of IL-1 and TNF-a from macrophages (Roth
and De Souza 2001; Sagy et al. 2013; Zhang et al. 2014).
Furthermore, septic shock is also associated with an
increased level of platelet-activating factor, thromboxane
A2, leukotrienes, macrophage inflammatory protein-1,
prostaglandin E2 (PGE2), cyclooxygenase (COX)-2
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mRNA and endothelin-1 (ET-1) (Dilshara et al. 2014;
Jesmin et al. 2014; Keller et al. 2006; Roth and De Souza
2001). Under pathological conditions, endotoxin stimulates
endothelin systems to release large amounts of endothelin
into the blood stream. Likewise, the levels of ETA and
ETB receptor mRNA are also elevated in some tissues
(Forni et al. 2005). LPS-induced sepsis impairs the integ-
rity of the endothelial barrier resulting in endothelial cell
injury, which contributes to greater permeability of endo-
thelial cells and impaired homeostasis, and induces the
release of cytokines and reactive oxygen species (ROS).
Plasma levels of ET-1 are elevated in septic patients and
are associated with the severity of the illness. Some authors
indicate a clear correlation between endothelin plasma
level and morbidity and mortality in septic patients (Pan
et al. 2012).
The Endothelin System
The endothelins are a family of 21 amino acid peptides
with three distinct isoforms: ET-1, ET-2 and ET-3. ET-1 is
the most abundant and the best described isoform. ET-2
and ET-3 were identified later and are not as well-studied
(Motte et al. 2006; Yanagisawa et al. 1988). ET-1 is pro-
duced in a variety of cells (Table 1) and there are many
factors which regulate its secretion (Table 2). Physical and
chemical stimulants activate ET-1 gene expression in
endothelial cells by the DNA binding of transcription
factors such as activator protein-1, GATA-2, smad,
hypoxia inducible factor-1 and NF-jB (Rodriguez-Pascual
et al. 2003; Wanecek et al. 2000; Wort et al. 2009).
Two types of endothelin receptors are found in mam-
mals, ETA and ETB receptors, which belong to the G
protein-coupled receptors family. ETA receptors are loca-
ted mostly in vascular smooth muscle cells (VSMC), where
they are responsible for potent vascular contraction
(Fig. 1), cell proliferation and a proinflammatory effect.
ETB receptors include two subtypes: ETB1, which is
expressed on endothelial cells and evokes NO-mediated
vasodilation, and ETB2, also present in VSMC, which
causes contraction (Hynynen and Khalil 2006; Yanagisawa
et al. 1988). Stimulation of ETB1 receptors also results in
the release of other vasodilatory factors such as prostacy-
clin (PGI2) and endothelium-derived hyperpolarizing
factor. Furthermore, it is suggested that endothelial ETB
receptors take part in ET-1 clearance, but findings are not
unequivocal (Hynynen and Khalil 2006; Kawanabe and
Nauli 2011; Ohkita et al. 2012).
So far, ETA and ETB receptors have been detected in
many cell types other than blood vessels (Table 1), but
predominantly in cardiovascular tissues (Hynynen and













































































































































































































































































































































































































































































































































































































































































































































42 Arch. Immunol. Ther. Exp. (2015) 63:41–52
123
influence on the function of many organs like the heart, the
kidneys, the lungs and the liver (Lima et al. 2011; Rodri-
guez et al. 2013). Apart from participating in the regulation
of vascular tone, endothelins take part in vascular,
myocardial and bone remodelling, inhibition of apoptosis
and salt-water retention. Furthermore, endothelins can
contribute to bronchoconstriction, angiogenesis and neu-
ropathic pain (Rodriguez et al. 2013; Thakkar et al. 2006).
ET-1 and ROS
It is known that ET-1 stimulates the production of ROS,
primarily superoxide anions (O2
-), and consequently leads
to the development of oxidative stress. When given intra-
venously, the peptide initially causes vasodilation of blood
vessels followed by their subsequent long lasting contrac-
tion, resulting in ischemia of internal organs and the
dysfunction of the endothelium. These changes can lead to
abundant ROS generation (Dong et al. 2005; Loomis et al.
2005; Lo´pez-Sepu´lveda et al. 2011; Thakali et al. 2005).
Some studies have shown the oxidative stress caused by
ET-1 to be associated with augmentation of lipid peroxi-
dation and reduction of intracellular GSH (glutathione) and
SH groups (Scalera et al. 2002; Viswanatha Swamy et al.
2011). According to the literature, both the ETA (Elm-
arakby et al. 2005) and ETB receptors (Dong et al. 2005)
mediate ROS generation. Callera et al. (2003) demon-
strated that elevated concentrations of ET-1 induce the
synthesis of O2
- through ETA receptors. Xu et al. (2003)
report a significant reduction in lipid peroxidation products
content in the ischemic myocardium after applying BQ123,
a blocker of the ETA receptor. Other authors note a
Table 2 Factors, which stimulate and inhibit release of ET-1
Factors stimulating release of ET-1 Factors inhibiting
release of ET-1
















a Duan et al. (2008), b Hukovic and Hadziselimovic (1998), c Hy-
nynen and Khalil (2006), d Maemura et al. (1992), e Motte et al.
(2006), f Shao et al. (2011), g Sugiura et al. (1989), h Yamashita et al.
(1993), i Yanagisawa et al. (1988), j Yoshizumi et al. (1989)
Fig. 1 ETA receptor-mediated VSMC signalling pathways. Activa-
tion of the ETA receptor stimulates phospholipase C (PLC) to
generate inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG)
from phosphatidylinositol 4.5-bisphosphate (PIP2). IP3 induces Ca
2?
outflow from intracellular stores in sarcoplasmic reticulum (SR).
Furthermore, the ETA receptor acts on nonselective plasmalemmal
Ca2? channels causing Ca2? input from the extracellular space.
Consequently, increased concentrations of Ca2? leads to the
contraction of VSMC. The activated ETA receptor also stimulates
cell growth. Production of DAG activates protein kinase C (PKC),
which is responsible for the mitogenic function of endothelin, and
which also induces a Ca2?-independent pathway of VSMC contrac-
tion involving calponin phosphorylation. PKC affects gene
transcription through activation of the Ras/Raf/MEK/MAPK cascade.
MAPK phosphorylates caldesmon, which increases VSMC contrac-
tion (Hynynen and Khalil 2006; Khalil 2011; Lima et al. 2011)
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reduction of lipid peroxidation in various organs during
oxidative stress when using this blocker (Briyal et al.
2011). BQ123 has been found to block increased produc-
tion of O2
- in ET-1-induced oxidative stress in the arteries
and veins of patients with coronary artery disease (Cerrato
et al. 2012), has been associated with a significant increase
in the concentration of total glutathione and superoxide
dismutase (SOD) activity after application (Briyal et al.
2011), as well as a significant increase in the activity of the
antioxidant enzymes SOD and catalase in cases of ET-1-
induced oxidative stress (Ozdemir et al. 2006).
Studies on blocking ETB receptors are ambiguous.
Wedgwood et al. (2001) note that the ETB receptor
antagonist (Res-701-3) increased the production of H2O2 in
the smooth muscle cell culture from the pulmonary artery,
but not in endothelial cells. However, other studies indicate
that the ETB receptor blockade reduces the ROS produc-
tion in various tissues (Dai et al. 2004). Moreover,
Piechota-Polanczyk et al. (2012) report a significant
increase in the concentration of GSH, but insignificant
increase in the ratio of GSH/GSSG in the rat heart after
application of BQ788. On the other hand, Leonard et al.
(2011, 2012) did not observe any changes in the concen-
tration of glutathione in rats after administration of BQ788.
The Proinflammatory Effect of ET-1
Several studies have demonstrated that ET-1 contributes to
the development of inflammatory processes in the vascular
wall. ET-1 has been found to be associated with an
inflammatory response involving activation of transcription
factors such as NF-jB and expression of proinflammatory
cytokines including TNF-a, IL-1 and IL-6 (Yeager et al.
2012). These transcription factors and proinflammatory
cytokines in turn stimulate ET-1 production (Virdis and
Schiffrin 2003). Bellisai et al. (2011) report that ET-1
increases the synthesis of TNF-a in macrophages and
monocytes. This cytokine enhances the inflammatory
response by stimulating the chemotaxis and phagocytosis
of macrophages, monocytes and neutrophils. Increased
production of ROS in different types of cells occurs via the
NF-jB, COX and NADPH oxidase-dependent pathways
(Donate et al. 2012; Kleniewska et al. 2013; Piechota and
Goraca 2011).
Recent studies have shown that the ETA receptor
antagonist BQ123 has a beneficial influence on the con-
centration of TNF-a (Ozdemir et al. 2006). Ford et al.
(2008) note that the ETA receptor blockade lowered the
concentration of TNF-a in patients after bypass grafting via
the antagonist BQ123. Chen et al. (2010) confirmed that
BQ123 inhibited the expression of TNF-a and IL-1b in the
lungs of rats during oxidative stress induced by
intraperitoneal administration of an extract from the ciga-
rette smoke. Moreover, an ETB receptor blockade may also
have an influence on TNF-a synthesis. In a recent study by
Tonari et al. (2012), BQ788 showed significant inhibition
of the expression of TNF-a when applied to patients with
damage to the optic nerve. However, Piechota-Polanczyk
et al. (2012) report no significant reduction in the con-
centrations of TNF-a in the rat heart following the
application of BQ788.
Furthermore, an excess amount of proinflammatory
cytokines activates prostaglandin production during
inflammatory responses in a number of cell types such as
vascular endothelial and smooth muscle cells. Prostaglan-
dins are synthetized by COX, which is also known as
prostaglandin endopeptidase synthase. In this process,
phospholipase A2 catalyses the release of arachidonic acid
(AA) from membrane phospholipids, while COX catalyzes
the conversion of AA into prostaglandins. There are two
COX isoforms: COX-1 is constitutively expressed under
normal conditions in the most tissues. This isoform takes
part in regulating normal physiological responses and
controls vascular homeostasis. COX-2 is not detectable in
most normal cells and tissues, but its expression increases
in inflammatory cells. Thus, COX-2 may play a crucial role
in the development of various inflammatory responses
including vascular inflammation. Recent studies have
indicated that ET-1 induces COX-2 expression and PGE2
release by MAPKs and NF-jB (Lin et al. 2013).
ET-1 enhances the expression of adhesion molecules on
vascular endothelial cells and stimulates the aggregation of
polymorphonuclear neutrophils (PMNs) contributing to
inflammation and endothelial dysfunction. Li et al. (2003)
postulate that ET-1 stimulates the arterial vascular adhe-
sion molecule-1 (VCAM-1) in hypertensive patients.
VCAM-1 and the intracellular adhesion molecule-1 induce
firm adhesion of inflammatory cells at the vascular surface
(Blankenberg et al. 2003). PMNs may contribute to myo-
cardial damage by releasing ROS, proteases and
arachidonic acid metabolites (Hansen 1995). Oktar et al.
(2000) indicate that ET-1 causes an accumulation of
PMNs, oxidative stress, and mucosal dysfunction in the rat
small intestine. Gonon et al. (2001) showed that the ET
receptor blockade attenuates the accumulation of neutro-
phils and myeloperoxidase activity in the ischemic
myocardium. It has been shown that the vascular injury
caused by carotid artery ligation results in vascular
inflammation and neointima formation. This action is
attenuated in vascular endothelial ET-1-knockout mice
(Anggrahini et al. 2009).
Increased ROS release contributes to endothelium dys-
function. Endothelial dysfunction occurs in cardiovascular
diseases such as atherosclerosis. Increased expression of
ET-1 was observed both in experimental models of
44 Arch. Immunol. Ther. Exp. (2015) 63:41–52
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atherosclerosis as well as in human atherosclerosis (Barton
et al. 2003) and its level correlated with the severity of the
atherosclerotic lesion. Haug et al. (1996) identify a higher
expression of ET-1 in human VSMC harvested from
human atherosclerotic coronary arteries than in cells from
non-atherosclerotic arteries. ET-1 was associated with
regions of the atherosclerotic plaque, particularly in regions
with high macrophage content (Dashwood and Tsui 2011).
It was shown that overexpression of ET-1 significantly
increased the atherosclerotic lesion size in apolipoprotein E
gene deleted mice (ApoE-/-) fed a high-fat diet. In this
case, increased endothelial ET-1 expression enhances an
increase in expression of genes associated with lipid syn-
thesis in the vasculature and accelerates the progression of
atherosclerosis (Simeone et al. 2011).
Li et al. (2013) have reported that ET-1 plays a role in
the development of atherosclerosis and abdominal aortic
aneurysm by decreasing high-density lipoprotein,
increasing oxidative stress and monocyte/macrophage
infiltration in both the aorta and aneurysms. So, plaque
formation and endothelial function can be restored in the
atherosclerosis model by the administration of ETA or
dual ETA/ETB receptor antagonists. Moreover, it has
been noted that tissue ET-1 concentration is more
important than serum ET-1 in predicting atherosclerosis in
patients with chronic kidney disease (Noshad et al. 2009).
Recently, a study indicated that ethanolic extract of
propolis inhibits atherosclerotic lesion formation in
ApoE-/- mice fed a high-fat diet, probably by regulating
the inflammatory reaction and inhibiting ET-1 (Fang et al.
2013). Overexpression of ET-1, particularly in the endo-
thelium of mice with atherosclerosis, is accompanied by a
decrease in endothelial signalling pathways responsible
for endothelium-dependent relaxation and an increase in
the activity of sensitive voltage-dependent potassium
channels (Mian et al. 2013). ROS are important physio-
logical messengers in vascular cells and their
overproduction contributes to the progression of athero-
sclerosis (Freund-Michel et al. 2013). ET-1 receptor
antagonists may be useful for prevention of various vas-
cular diseases (Kitada et al. 2009, 2012).
ET-1 and Endothelin Receptor Antagonists in Sepsis
Recently, studies have addressed the role of endothelins
and blockers of their receptors in the development of
sepsis. During endotoxaemia, plasma endothelin level is
increased in various species (Kaszaki et al. 1997; Pan et al.
2012; Piechota-Polan´czyk and Gora˛ca 2012). In experi-
mental models, endotoxin induces the expression of
preproendothelin-1 mRNA in the lung and heart (Kaddoura
et al. 1996). Infusion of ET-1 in septic shock contributed to
the dysfunction of several vital organs such as liver, lung,
heart and kidney (Fenhammar et al. 2011; Piechota-Pola-
nczyk et al. 2012). It has been indicated that the infusion of
ET-1 in humans causes cardiovascular changes in part
resembling those observed during sepsis i.e. decreased
cardiac output, vasoconstriction in the pulmonary artery,
impairment of renal and splanchnic circulation (Bomberg
et al. 2013; Ross 2012; Schuuring et al. 2013). It has been
demonstrated in animal experiments that dual ETA/ETB
endothelin blockade during endotoxaemia improves car-
diopulmonary function, reduces pulmonary hypertension
and lung injury and attenuates intestinal and liver micro-
circulatory dysfunction (Kuklin et al. 2005; Sa´nchez-Etayo
et al. 2012). Also ETA receptor blockade alone improves
the function of the lungs (Mercier et al. 2010), kidney
(Rullman et al. 2010), heart (Vaneˆckova´ et al. 2005) and
aorta (Tirapelli et al. 2008).
Endothelin receptor antagonists (ERAs) are a new,
promising class of medicines which block the ETA and
ETB endothelin receptors with varying degrees of selec-
tivity. They form a large group consisting of nearly 40 or
more compounds, and part of them is currently under
investigation (Hynynen and Khalil 2006; Khalil 2011;
Motte et al. 2006) as potential therapeutic objects in clin-
ical trials (see Table 3). ERAs act on various
pathophysiological mechanisms (Table 4), three of which
recommended for treatment of pulmonary arterial hyper-
tension, bosentan, ambrisentan and macitentan, are already
on the world pharmaceutical market (Motte et al. 2006;
Patel and McKeage 2014). However, the nonselective
ERAs, bosentan and tezosentan, and selective antagonists,
BQ123 and BQ788, are currently receiving the most
attention with regard to the effect of ERAs on the pro-
gression of sepsis.
Bosentan
In 2001, bosentan (Tracleer) became the first ERA to be
registered in the USA as an oral medicine for patients with
pulmonary arterial hypertension of functional class III/IV
(Dupuis and Hoeper 2008; Motte et al. 2006). Many studies
have shown a significant improvement in functional class
and exercise capacity, as well as haemodynamic, Doppler
and echocardiographic parameters after treatment with
bosentan. Despite having side effects such as increases in
liver transaminase content, headache, peripheral oedema,
dizziness, nasal congestion and nausea, bosentan therapy is
generally regarded as beneficial (Montani et al. 2013;
Motte et al. 2006). Bosentan also has been found to exert a
positive therapeutic influence on the treatment of systemic
sclerosis (scleroderma) and other disorders (Cozzi et al.
2013) (Table 3).
Arch. Immunol. Ther. Exp. (2015) 63:41–52 45
123
A common feature of sepsis is microcirculatory dys-
function. However, Krejci et al. (2003) note improved
microcirculatory blood flow in the pancreas, gastric, skel-
etal muscle and colon mucosa of septic pigs treated with
bosentan. Further, Iskit et al. (2004) report that bosentan at
a dose of 30 mg/kg b.w. decreases caecal ligation and
reduce liver, kidney and spleen injury, improving survival
(p \ 0.05) in a mouse model of polymicrobial sepsis. They
also suggest that antagonism of endothelin receptors during
the hypodynamic phase of septic shock gives much better
results. More detailed data provided by Keller et al. (2006)
confirm that the administration of LPS results in increased
expressions of ET-1, iNOS, and COX-2 mRNA. They also
report a significant inhibition of the up-regulation of ET-1,
iNOS, and COX-2 mRNA after treatment of rats with
30 mg/kg b.w. bosentan, thus demonstrating its anti-
inflammatory and therapeutic properties.
Tezosentan
The first study concerning the effects of tezosentan on the
cardiovascular system in sepsis was conducted by Chin
et al. (2002). During endotoxaemia, endothelin antagonism
with this ERA maintained renal and cardiac functions,
preventing decreases in cardiac index, renal blood flow,
Table 3 Main ERAs in clinical and preclinical trials




ETA Idiopathic pulmonary fibrosis (phase I clinical
study)22
Treatment of pulmonary arterial hypertension associated
with spironolactone (ARIES trials)17, therapy of




ETA Metastatic hormone-refractory prostate cancer
(phase III clinical study)2
Diabetic nephropathy: reduced albuminuria (phase II
clinical study)1, 13
Castration-resistant prostate cancer and bone
metastases (phase III clinical study)21
Cerebrovascular dysfunction in diabetes: improved
cerebrovascular relaxation (preclinical study)15
Early atherosclerosis: improved endothelial function and
inhibited plaque progression (phase I clinical study)24, 33
Avosentan (SPP
301)
ETA Diabetic and non-diabetic chronic kidney
disease (ASCEND trial)12
Glaucoma (preclinical study)14, 31
Bosentan
(Tracleer)
ETA/ETB Pulmonary hypertension associated with fibrotic
idiopathic interstitial pneumonia (phase 0
clinical study)5
Ovarian ischaemia/reperfusion (I/R) injury: limited
oxidative damage and I/R injury (preclinical study)27
Rheumatoid arthritis: antinociceptive and anti-inflammatory
activity (preclinical study)9




ETA Prevention of occurrence of cerebral vasospasm after aneurysmal subarachnoid haemorrhage: controversial
results (CONSCIOUS-2 and halted CONSCIOUS-3 trials)16, 28
Darusentan (LU-
135252)
ETA Resistant hypertension: significantly decreased blood pressure, but serious adverse events (DORADO trial)7
Macitentan
(Opsumit)
ETA/ETB Idiopathic pulmonary fibrosis (MUSIC trial)23 Ovarian cancer: inhibited progression, reduced tumour
weight (preclinical study)10, 11
Tezosentan (RO
61-0612)
ETA/ETB Right ventricular failure (TACTICS trial)6, 19 Ischemic cardiomyopathy: protective properties (preclinical




ETA Metastatic and non-metastatic hormone- and
castration-resistant prostate cancer (phase III
clinical study)18, 20, 26
Colorectal cancer (preclinical study)8
Ovarian cancer (phase II clinical study)4
Non-small cell lung cancer (phase II clinical
study)3
1 Braun et al. (2012), 2 Carducci et al. (2007), 3 Chouaid et al. (2011), 4 Cognetti et al. (2013), 5 Corte et al. (2014), 6 Denault et al. (2013),
7 Grassi (2011), 8 Haque et al. (2013), 9 Imhof et al. (2011), 10 Kim et al. (2011), 11 Kim et al. (2012), 12 Kohan and Pollock (2013), 13 Kohan
et al. (2011), 14 Konieczka et al. (2011), 15 Li et al. (2011), 16 Macdonald et al. (2013), 17 Maron et al. (2013), 18 Miller et al. (2013), 19 Motte
et al. (2006), 20 Nelson et al. (2012), 21 Quinn et al. (2013), 22 Raghu et al. (2013a), 23 Raghu et al. (2013b), 24 Reriani et al. (2010), 25 Ryu et al.
(2009), 26 Schelman et al. (2011), 27 Sengul et al. 2013, 28 Shen et al. (2013), 29 Singh et al. (2014), 30 Takatsuki et al. (2013), 31 Wang et al.
(2011), 32 Wong et al. (2008), 33 Yoon et al. (2013)
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glomerular filtration rate and increased systemic vascular
resistance in neonatal piglets (Chin et al. 2002). Further
research demonstrated that tezosentan (10 mg/kg b.w)
prevents mesenteric ischemia in septic mice. It
significantly (p = 0.0046) attenuated decreases in mesen-
teric blood flow and limited injury to organs such as the
liver, kidney and spleen. However, in this study, despite
what was expected, tezosentan did not reduce ROS gen-
eration (Erdem et al. 2007). Other sepsis studies on pigs
have brought similar effects, confirming that application of
tezosentan results in improved intestinal and renal micro-
circulation, contributes to increased portal vein flow and
decreased pulmonary capillary wedge pressure, and pre-
serves cardiac index. Moreover, pH and arterial lactate
values were better compared to the control (Andersson
et al. 2008; Fenhammar et al. 2008). It is also significant
that this dual blocker had no influence on TNF-a, IL-6 or
IL-10 plasma levels, nor angiotensin II or aldosterone
plasma concentration, in this model of sepsis (Fenhammar
et al. 2008). A recent investigation using tezosentan and the
selective ETA antagonist, TBC3711 revealed no
improvement in the liver and ileum microvascular blood
flow during selective antagonism, but it showed marked
amelioration after tezosentan. These findings highlight the
special role of the ETB receptor in mediating the micro-
circulatory failure in this area (Andersson et al. 2010).
BQ123 and BQ788
Selective endothelin receptor blockers like BQ123 and
BQ788 have also been used in sepsis studies: the former
being an ETA receptor antagonist and the latter an ETB
receptor blocker. Hirata and Ishimaru (2002) report that
BQ123 does not increase survival in a rat septic shock
model, due to lack of improvement in LPS-induced pro-
found hypotension. However, a dual blockade of
endothelin receptors helped maintain normal mean arterial
pressure. The authors also suggest that this effect does not
depend on iNOS-derived NO (Hirata and Ishimaru, 2002).
Similarly, Nitescu et al. (2008) note that while BQ123 did
not prevent endotoxin-induced hypotension, BQ788 did, by
increasing mean arterial pressure in septic rats. Moreover,
marked decrease (p \ 0.05) of renal blood flow was
observed in the group treated with both BQ788 and LPS,
which may indicate that the ETB receptor is responsible for
renal vasodilation and maintenance of normal renal blood
flow (Nitescu et al. 2008).
Some authors suggest that oxidative stress in sepsis is
mediated by ET-1 and ETA receptors. Studies on a rat
model have shown that LPS markedly elevates lipid per-
oxidation products, TNF-a and H2O2 concentration in the
lung, and BQ123 administration resulted in a distinct
decrease of these parameters (p \ 0.05), except for lipid
peroxidation products level, which remained elevated. This
ETA blocker also reduced TNF-a level in lung and plasma.
Furthermore, a lower dose of BQ123 (0.5 mg/kg) was
Table 4 The effects of endothelin receptor blockers on various
pathophysiological mechanisms in sepsis—summary
Blocker Selectivity Effect References























Chen et al. (2010),





Chen et al. (2010)







Iskit et al. (2004),
Krejci et al.
(2003)


















Chin et al. (2002),
Kuklin et al.
(2005)
BQ788 ETB Reduction in the
ROS production in
various tissues
Dai et al. (2004)
Increase of mean
arterial pressure
Nitescu et al. (2008)
Protective and anti-
inflammatory
effects in the brain
tissue
Naito et al. (2014)
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found to be more effective than higher dose of 1 mg/kg,
and also prevented lung oedema development (p \ 0.01)
(Piechota et al. 2011; Piechota-Polan´czyk and Gora˛ca
2012). On the other hand, the same study based on heart
tissue demonstrated a significant reduction in lipid perox-
idation products and TNF-a, but not in H2O2 concentration,
after BQ123 administration in experimental sepsis (Pie-
chota-Polanczyk et al. 2012). These performance
differences are probably associated with different antioxi-
dant enzymes activities in the lung and heart.
Moreover, ETB receptor antagonism with BQ788 also
reduced amplified amount of ROS, lowering lipid peroxi-
dation products and H2O2 concentration. However, BQ788
did not influence increased concentration of TNF-a and
neither BQ123 nor BQ788 affected LPS-induced activation
of NF-jB pathway. However, Naito et al. (2014) note the
protective effects of BQ788, including inhibition of neu-
roblast apoptosis, c-FOS expression, number of reactive
microglia and distinctly diminished TNF-a level in mouse
brain tissue during sepsis. These findings may suggest that
in the heart, the ETA receptor is more involved in secretion
of TNF-a than ETB. Furthermore, presumably both endo-
thelin receptors in heart tissue stimulate ROS generation by
some other signalling pathways than NF-jB. Nevertheless,
the blockage of ETA receptor reduces ROS production and
improves tissue antioxidant properties (Piechota-Polanczyk
et al. 2012). These findings also confirm to some extent that
ET-1 is strongly involved in the pathogenesis of septic
shock, but the close links between factors inducing sepsis
and increased production of ET-1 are still unclear.
Towards the End
A very recent study has revealed that the oedema-pro-
moting effects of ET-1 might be related to augmented level
of heparin-binding protein (HBP) accompanying sepsis.
HBP, also termed CAP37 or azurocidin is a protein
released from neutrophils, which induces vascular hyper-
permeability and contributes to oedema formation during
endotoxaemia. Until now, it was believed that ET-1 indu-
ces vascular leakage, but the mechanisms of this action
were not established. Using a porcine sepsis model, Pers-
son et al. (2014) report a significant decrease of HBP
plasma level, as well as reduced pulmonary oedema, in
animals treated with tezosentan compared to those who
received ET-1 or the ETB receptor agonist sarafotoxin 6c,
both of which caused a dose-dependent increase in HBP
levels similar to those observed in sepsis. These findings
suggest that stimulation of both endothelin receptors acti-
vates reactions which lead to augmented secretion of HBP
and this process may be abolished by nonselective ERA
(Persson et al. 2014).
More than 20 years ago, ET-1 was identified as the first
endothelium-derived contracting factor. Shortly after, two
receptor subtypes, ETA and ETB, were discovered, which
permitted the development of orally active ET-1 receptor
antagonists. One of the first was the nonselective ETA/
ETB-receptor antagonist, bosentan (Tracleer), available
to patients in 2001. Since then, although many ERAs have
been described, not all of them are in clinical use. A novel
ERA, macitentan (Opsumit), is a very potent nonslective
blocker, with high lipophilicity (Montani et al. 2013)
‘‘sustained receptor binding and enhanced tissue penetra-
tion properties’’ (Sidharta et al. 2013). It is the newest and
safest registered ERA (Patel and McKeage 2014), but its
specific properties have not yet been studied in condition of
sepsis. Similarly, a potent ETA receptor antagonist, am-
brisentan (Letairis, Volibris) may present favourable
effects in sepsis (Montani et al. 2013; Elshaboury and
Anderson 2013).
New applications for this group of medicines still
remain an interesting subject of study. Antibiotics, fluids
and vasopressors are most commonly used in the treatment
of sepsis. Recent anti-inflammatory strategies such as high-
dose corticosteroids, anti-TNF-a, IL-1-based therapies or
activated protein C, have proved to be disappointing (Xie
et al. 2014). Effective clinical applications of endothelin
receptor antagonists need a more thorough understanding
of the physiology and pathophysiology of the ET-1 system.
Endothelins, HBP and other, yet unidentified, factors
involved in the bacterial toxin activation of the endothelin
system might represent the main target for sepsis therapy in
the future.
Acknowledgments This work was supported by Medical University
of Lodz Grant No. 503/0-079-03/503-01 and Grant No. 502-03/0-079-
03/502-04-017.
Conflict of interest The authors declare that they have no conflict
of interest.
Open Access This article is distributed under the terms of the
Creative Commons Attribution License which permits any use, dis-
tribution, and reproduction in any medium, provided the original
author(s) and the source are credited.
References
Andersson A, Fenhammar J, Frithiof R et al (2008) Mixed endothelin
receptor antagonism with tezosentan improves intestinal micro-
circulation in endotoxemic shock. J Surg Res 149:138–147
Andersson A, Fenhammar J, Weitzberg E et al (2010) Endothelin-
mediated gut microcirculatory dysfunction during porcine
endotoxaemia. Br J Anaesth 105:640–647
Anggrahini DW, Emoto N, Nakayama K et al (2009) Vascular
endothelial cell-derived endothelin-1 mediates vascular inflam-
mation and neointima formation following blood flow cessation.
Cardiovasc Res 82:143–151
48 Arch. Immunol. Ther. Exp. (2015) 63:41–52
123
Barton M, Traupe T, Haudenschild CC (2003) Endothelin, hyper-
cholesterolemia and atherosclerosis. Coron Artery Dis
14:477–490
Bellisai F, Morozzi G, Scaccia F et al (2011) Evaluation of the effect
of bosentan treatment on proinflammatory cytokine serum levels
in patients affected by systemic sclerosis. Int J Immunopathol
Pharmacol 24:261–264
Blankenberg S, Barbaux S, Tiret L (2003) Adhesion molecules and
atherosclerosis. Atherosclerosis 170:191–203
Bomberg H, Bierbach B, Flache S et al (2013) Endothelin and
vasopressin influence splanchnic blood flow distribution during
and after cardiopulmonary bypass. J Thorac Cardiovasc Surg
145:539–547
Braun L, Sood V, Hogue S et al (2012) High burden and unmet
patient needs in chronic kidney disease. Int J Nephrol Renovasc
Dis 5:151–163
Briyal S, Philip T, Gulati A (2011) Endothelin-A receptor antagonists
prevent amyloid-b-induced increase in ETA receptor expression,
oxidative stress, and cognitive impairment. J Alzheimers Dis
23:491–503
Callera GE, Touyz RM, Teixeira SA et al (2003) ETA receptor
blockade decreases vascular superoxide generation in DOCA-
salt hypertension. Hypertension 42:811–817
Carducci MA, Saad F, Abrahamsson PA et al (2007) A phase 3
randomized controlled trial of the efficacy and safety of
atrasentan in men with metastatic hormone-refractory prostate
cancer. Cancer 110:1959–1966
Cerrato R, Cunnington C, Crabtree MJ et al (2012) Endothelin-1
increases superoxide production in human coronary artery
bypass grafts. Life Sci 91:723–728
Chen Y, Hanaoka M, Droma Y et al (2010) Endothelin-1 receptor
antagonists prevent the development of pulmonary emphysema
in rats. Eur Respir J 35:904–912
Chin A, Radhakrishnan J, Fornell L et al (2002) Effects of tezosentan,
a dual endothelin receptor antagonist, on the cardiovascular and
renal systems of neonatal piglets during endotoxic shock.
J Pediatr Surg 37:482–487
Chouaid C, Nathan F, Pemberton K et al (2011) A phase II,
randomized, multicenter study to assess the efficacy, safety, and
tolerability of zibotentan (ZD4054) in combination with pemetr-
exed in patients with advanced non-small cell lung cancer.
Cancer Chemother Pharmacol 67:1203–1208
Cognetti F, Bagnato A, Colombo N et al (2013) A Phase II,
randomized, double-blind study of zibotentan (ZD4054) in
combination with carboplatin/paclitaxel versus placebo in com-
bination with carboplatin/paclitaxel in patients with advanced
ovarian cancer sensitive to platinum-based chemotherapy (AGO-
OVAR 2.14). Gynecol Oncol 130:31–37
Corte TJ, Keir GJ, Dimopoulos K et al (2014) Bosentan in pulmonary
hypertension associated with fibrotic idiopathic interstitial
pneumonia (BPHIT). Am J Respir Crit Care Med 190:208–217
Cozzi F, Pigatto E, Rizzo M et al (2013) Low occurrence of digital
ulcers in scleroderma patients treated with bosentan for
pulmonary arterial hypertension: a retrospective case-control
study. Clin Rheumatol 32:679–683
Dai X, Galligan JJ, Watts SW et al (2004) Increased O2
•_ production
and upregulation of ETB receptors by sympathetic neurons in
DOCA-salt hypertensive rats. Hypertension 43:1048–1054
Dashwood MR, Tsui JC (2011) Further evidence for a role of
endothelin-1 (ET-1) in critical limb ischaemia. J Cell Commun
Signal 5:45–49
Denault AY, Pearl RG, Michler RE et al (2013) Tezosentan and right
ventricular failure in patients with pulmonary hypertension
undergoing cardiac surgery: the TACTICS trial. J Cardiothorac
Vasc Anesth 27:1212–1217
Dilshara MG, Lee KT, Jayasooriya RG et al (2014) Downregulation
of NO and PGE2 in LPS-stimulated BV2 microglial cells by
trans-isoferulic acid via suppression of PI3 K/Akt-dependent
NF-jB and activation of Nrf2-mediated HO-1. Int Immunophar-
macol 18:203–211
Donate PB, Cunha TM, Verri WA Jr et al (2012) Bosentan, an
endothelin receptor antagonist, ameliorates collagen-induced
arthritis: the role of TNF-a in the induction of endothelin system
genes. Inflamm Res 61:337–348
Dong F, Zhang X, Wold LE et al (2005) Endothelin-1 enhances
oxidative stress, cell proliferation and reduces apoptosis in
human umbilical vein endothelial cells: role of ETB receptor,
NADPH oxidase and caveolin-1. Br J Pharmacol 145:
323–333
Duan J, Xu H, Dai S et al (2008) Phytoestrogen alpha-zearalanol
inhibits homocysteine-induced endothelin-1 expression and
oxidative stress in human umbilical vein endothelial cells.
Atherosclerosis 197:549–555
Dupuis J, Hoeper MM (2008) Endothelin receptor antagonists in
pulmonary arterial hypertension. Eur Respir J 31:407–415
Ehrenreich H, Burd PR, Rottem M et al (1992) Endothelins belong to
the assortment of mast cell-derived and mast cell-bound
cytokines. New Biol 4:147–156
Elmarakby AA, Loomis ED, Pollock JS et al (2005) NADPH oxidase
inhibition attenuates oxidative stress but not hypertension
produced by chronic ET-1. Hypertension 45:283–287
Elshaboury SM, Anderson JR (2013) Ambrisentan for the treatment
of pulmonary arterial hypertension: improving outcomes. Patient
Prefer Adherence 7:401–409
Endo T, Uchida Y, Matsumoto H et al (1992) Regulation of
endothelin-1 synthesis in cultured guinea pig airway epithelial
cells by various cytokines. Biochem Biophys Res Commun
186:1594–1599
Erdem A, Meltem Sevgili A, Akbiyik F et al (2007) Tezosentan
attenuates organ injury and mesenteric blood flow decrease in
endotoxemia and cecal ligation and puncture. J Surg Res
141:211–219
Fang Y, Sang H, Yuan N et al (2013) Ethanolic extract of propolis
inhibits atherosclerosis in ApoE-knockout mice. Lipids Health
Dis 12:123
Fenhammar J, Andersson A, Frithiof R et al (2008) The endothelin
receptor antagonist tezosentan improves renal microcirculation
in a porcine model of endotoxemic shock. Acta Anaesthesiol
Scand 52:1385–1393
Fenhammar J, Andersson A, Forestier J et al (2011) Endothelin
receptor A antagonism attenuates renal medullary blood flow
impairment in endotoxemic pigs. PLoS ONE 6:e21534
Ford RL, Mains IM, Hilton EJ et al (2008) Endothelin-A receptor
inhibition after cardiopulmonary bypass: cytokines and receptor
activation. Ann Thorac Surg 86:1576–1583
Forni M, Mazzola S, Ribeiro LA et al (2005) Expression of
endothelin-1 system in a pig model of endotoxic shock. Regul
Pept 131:89–96
Freund-Michel V, Guibert C, Dubois M et al (2013) Reactive oxygen
species as therapeutic targets in pulmonary hypertension. Ther
Adv Respir Dis 7:175–200
Gonon AT, Gourine AV, Middelveld RJ et al (2001) Limitation of
infarct size and attenuation of myeloperoxidase activity by an
endothelin A receptor antagonist following ischaemia and
reperfusion. Basic Res Cardiol 96:454–462
Grassi G (2011) Selective endothelin receptor blockade in resistant
hypertension: results of the DORADO trial. Expert Opin
Pharmacother 12:153–155
Hansen PR (1995) Role of neutrophils in myocardial ischemia and
reperfusion. Circulation 91:1872–1885
Arch. Immunol. Ther. Exp. (2015) 63:41–52 49
123
Haque SU, Dashwood MR, Heetun M et al (2013) Efficacy of the specific
endothelin A receptor antagonist zibotentan (ZD4054) in colorectal
cancer: a preclinical study. Mol Cancer Ther 12:1556–1567
Haug C, Voisard R, Lenich A et al (1996) Increased endothelin
release by cultured human smooth muscle cells from athero-
sclerotic coronary arteries. Cardiovasc Res 31:807–813
Hirata Y, Ishimaru S (2002) Effects of endothelin receptor antagonists
on endothelin-1 and inducible nitric oxide synthase genes in a rat
endotoxic shock model. Clin Sci 103(Suppl 48):332S–335S
Hukovic N, Hadziselimovic R (1998) Endothelin 1 action on isolated
rat stomach and the role of calcium ions in ET 1 induced
depolarization of smooth muscle cells BC3H1. Biochem Mol
Biol Int 46:877–886
Hynynen MM, Khalil RA (2006) The vascular endothelin system in
hypertension–recent patents and discoveries. Recent Pat Cardio-
vasc Drug Discov 1:95–108
Imhof AK, Glu¨ck L, Gajda M et al (2011) Potent anti-inflammatory
and antinociceptive activity of the endothelin receptor antagonist
bosentan in monoarthritic mice. Arthritis Res Ther 13:R97
Iskit AB, Senel I, Sokmensuer C et al (2004) Endothelin receptor
antagonist bosentan improves survival in a murine caecal
ligation and puncture model of septic shock. Eur J Pharmacol
506:83–88
Jesmin S, Shimojo N, Yamaguchi N et al (2014) Effects of protease
activated receptor (PAR)2 blocking peptide on endothelin-1
levels in kidney tissues in endotoxemic rat mode. Life Sci
102:127–133
Kaddoura S, Curzen NP, Evans TW et al (1996) Tissue expression of
endothelin-1 mRNA in endotoxaemia. Biochem Biophys Res
Commun 218:641–647
Kaszaki J, Wolfa´rd A, Boros M et al (1997) Effects of antiendothelin
treatment on the early hemodynamic changes in hyperdynamic
endotoxemia. Acta Chir Hung 36:152–153
Kawanabe Y, Nauli SM (2011) Endothelin. Cell Mol Life Sci
68:195–203
Keller S, Karaa A, Paxian M et al (2006) Inhibition of endothelin-
1-mediated up-regulation of iNOS by bosentan ameliorates
endotoxin-induced liver injury in cirrhosis. Shock 25:306–313
Khalil RA (2011) Modulators of the vascular endothelin receptor in
blood pressure regulation and hypertension. Curr Mol Pharmacol
4:176–186
Kim SJ, Kim JS, Kim SW et al (2011) Macitentan (ACT-064992), a
tissue-targeting endothelin receptor antagonist, enhances thera-
peutic efficacy of paclitaxel by modulating survival pathways in
orthotopic models of metastatic human ovarian cancer. Neopla-
sia 13:167–179
Kim SJ, Kim JS, Kim SW et al (2012) Antivascular therapy for
multidrug-resistant ovarian tumors by macitentan, a dual endo-
thelin receptor antagonist. Transl Oncol 5:39–47
Kitada K, Yui N, Matsumoto C et al (2009) Inhibition of endothelin
ETB receptor system aggravates neointimal hyperplasia after
balloon injury of rat carotid artery. J Pharmacol Exp Ther
331:998–1004
Kitada K, Ohkita M, Matsumura Y (2012) Pathological importance of
the endothelin-1/ET(B) receptor system on vascular diseases.
Cardiol Res Pract 2012:731970
Kleniewska P, Piechota-Polanczyk A, Michalski L et al (2013)
Influence of block of NF-kappa B signaling pathway on
oxidative stress in the liver homogenates. Oxid Med Cell
Longev 2013:308358
Kohan DE, Pollock DM (2013) Endothelin antagonists for diabetic
and non-diabetic chronic kidney disease. Br J Clin Pharmacol
76:573–579
Kohan DE, Pritchett Y, Molitch M et al (2011) Addition of atrasentan
to renin-angiotensin system blockade reduces albuminuria in
diabetic nephropathy. J Am Soc Nephrol 22:763–772
Konieczka K, Meyer P, Schoetzau A et al (2011) Effect of
avosentan (SPP-301) in porcine ciliary arteries. Curr Eye Res
36:118–124
Krejci V, Hiltebrand LB, Erni D et al (2003) Endothelin receptor
antagonist bosentan improves microcirculatory blood flow in
splanchnic organs in septic shock. Crit Care Med 31:203–210
Kuklin V, Kirov M, Sovershaev M et al (2005) Tezosentan-induced
attenuation of lung injury in endotoxemic sheep is associated
with reduced activation of protein kinase C. Crit Care 9:R211–
R217
Leonard MG, Briyal S, Gulati A (2011) Endothelin B receptor
agonist, IRL-1620, reduces neurological damage following
permanent middle cerebral artery occlusion in rats. Brain Res
1420:48–58
Leonard MG, Briyal S, Gulati A (2012) Endothelin B receptor
agonist, IRL-1620, provides long-term neuroprotection in cere-
bral ischemia in rats. Brain Res 1464:14–23
Li L, Chu Y, Fink GD et al (2003) Endothelin-1 stimulates arterial
VCAM-1 expression via NADPH oxidase-derived superoxide in
mineralocorticoid hypertension. Hypertension 42:997–1003
Li W, Sachidanandam K, Ergul A (2011) Comparison of selective
versus dual endothelin receptor antagonism on cerebrovascular
dysfunction in diabetes. Neurol Res 33:185–191
Li MW, Mian MO, Barhoumi T et al (2013) Endothelin-1 overex-
pression exacerbates atherosclerosis and induces aortic
aneurysms in apolipoprotein E knockout mice. Arterioscler
Thromb Vasc Biol 33:2306–2315
Lima VV, Giachini FR, Hardy DM et al (2011) O-GlcNAcylation: a
novel pathway contributing to the effects of endothelin in the
vasculature. Am J Physiol Regul Integr Comp Physiol
300:R236–R250
Lin CC, Hsieh HL, Shih RH et al (2013) Up-regulation of COX-2/
PGE2 by endothelin-1 via MAPK-dependent NF-jB pathway in
mouse brain microvascular endothelial cells. Cell Commun
Signal 11:8
Liu B, Zhou J, Chen H et al (1997) Expression and cellular location of
endothelin-1 mRNA in rat liver following endotoxemia. Chin
Med J 110:932–935
Loomis ED, Sullivan JC, Osmond DA et al (2005) Endothelin
mediates superoxide production and vasoconstriction through
activation of NADPH oxidase and uncoupled nitric-oxide
synthase in the rat aorta. J Pharmacol Exp Ther 315:1058–1064
Lo´pez-Sepu´lveda R, Go´mez-Guzma´n M, Zarzuelo MJ et al (2011)
Red wine polyphenols prevent endothelial dysfunction induced
by endothelin-1 in rat aorta: role of NADPH oxidase. Clin Sci
120:321–333
Macdonald RL, Higashida RT, Keller E et al (2013) Randomised trial
of clazosentan, an endothelin receptor antagonist, in patients
with aneurysmal subarachnoid hemorrhage undergoing surgical
clipping (CONSCIOUS-2). Acta Neurochir Suppl 115:27–31
Maemura K, Kurihara H, Morita T et al (1992) Production of
endothelin-1 in vascular endothelial cells is regulated by factors
associated with vascular injury. Gerontology 38(Suppl 1):29–35
Maron BA, Waxman AB, Opotowsky AR et al (2013) Effectiveness
of spironolactone plus ambrisentan for treatment of pulmonary
arterial hypertension (from the [ARIES] study 1 and 2 trials).
Am J Cardiol 112:720–725
Mercier O, Sage E, Izziki M et al (2010) Endothelin A receptor
blockade improves regression of flow-induced pulmonary vas-
culopathy in piglets. J Thorac Cardiovasc Surg 140:677–683
Mian MO, Idris-Khodja N, Li MW et al (2013) Preservation of
endothelium-dependent relaxation in atherosclerotic mice with
endothelium-restricted endothelin-1 overexpression. J Pharmacol
Exp Ther 347:30–37
Miller K, Moul JW, Gleave M et al (2013) Phase III, randomized,
placebo-controlled study of once-daily oral zibotentan (ZD4054)
50 Arch. Immunol. Ther. Exp. (2015) 63:41–52
123
in patients with non-metastatic castration-resistant prostate
cancer. Prostate Cancer Prostatic Dis 16:187–192
Montani D, Gu¨nther S, Dorfmu¨ller P et al (2013) Pulmonary arterial
hypertension. Orphanet J Rare Dis 8:97
Motte S, McEntee K, Naeije R (2006) Endothelin receptor antago-
nists. Pharmacol Ther 110:386–414
Naito Y, Yoshioka K, Tanaka K et al (2014) Endothelin B receptor-
mediated encephalopathic events in mouse sepsis model. Life
Sci. doi:10.1016/j.lfs.2014.03.012
Nelson JB, Fizazi K, Miller K et al (2012) Phase 3, randomized,
placebo-controlled study of zibotentan (ZD4054) in patients with
castration-resistant prostate cancer metastatic to bone. Cancer
118:5709–5718
Nitescu N, Grimberg E, Ricksten SE et al (2008) Endothelin B
receptors preserve renal blood flow in a normotensive model of
endotoxin-induced acute kidney dysfunction. Shock 29:402–409
Noshad H, Argani H, Nezami N et al (2009) Arterial atherosclerosis
in patients with chronic kidney disease and its relationship with
serum and tissue endothelin-1. Iran J Kidney Dis 3:203–209
Ohkita M, Tawa M, Kitada K et al (2012) Pathophysiological roles of
endothelin receptors in cardiovascular diseases. J Pharmacol Sci
119:302–313
Oktar BK, Cos¸kun T, Bozkurt A et al (2000) Endothelin-1-induced
PMN infiltration and mucosal dysfunction in the rat small
intestine. Am J Physiol Gastrointest Liver Physiol 279:G483–
G491
Ozdemir R, Parlakpinar H, Polat A et al (2006) Selective endothelin
A (ETA) receptor antagonist (BQ-123) reduces both myocardial
infarct size and oxidant injury. Toxicology 219:142–149
Pan C, Wang J, Liu W et al (2012) Low tidal volume protects
pulmonary vasomotor function from ‘‘second-hit’’ injury in acute
lung injury rats. Respir Res 13:77
Patel T, McKeage K (2014) Macitentan: first global approval. Drugs
74:127–133
Persson BP, Halldorsdottir H, Lindbom L et al (2014) Heparin-
binding protein (HBP/CAP37): a link to endothelin-1 in
endotoxemia-induced pulmonary oedema? Acta Anaesthesiol
Scand 58:549–559
Piechota A, Goraca A (2011) Influence of nuclear factor-jB
inhibition on endothelin-1 induced lung edema and oxidative
stress in rats. J Physiol Pharmacol 62:183–188
Piechota A, Polan´czyk A, Goraca A (2011) Protective effects of
endothelin-A receptor antagonist BQ123 against LPS-induced
oxidative stress in lungs. Pharmacol Rep 63:494–500
Piechota-Polan´czyk A, Gora˛ca A (2012) Influence of specific
endothelin-1 receptor blockers on hemodynamic parameters
and antioxidant status of plasma in LPS-induced endotoxemia.
Pharmacol Rep 64:1434–1441
Piechota-Polanczyk A, Kleniewska P, Gora˛ca A (2012) The influence
of ETA and ETB receptor blockers on LPS-induced oxidative
stress and NF-jB signaling pathway in heart. Gen Physiol
Biophys 31:271–278
Quinn DI, Tangen CM, Hussain M et al (2013) Docetaxel and
atrasentan versus docetaxel and placebo for men with advanced
castration-resistant prostate cancer (SWOG S0421): a random-
ised phase 3 trial. Lancet Oncol 14:893–900
Raghu G, Behr J, Brown KK et al (2013a) Treatment of idiopathic
pulmonary fibrosis with ambrisentan: a parallel, randomized
trial. Ann Intern Med 158:641–649
Raghu G, Million-Rousseau R, Morganti A et al (2013b) Macitentan
for the treatment of idiopathic pulmonary fibrosis: the random-
ised controlled MUSIC trial. Eur Respir J 42:1622–1632
Reriani M, Raichlin E, Prasad A et al (2010) Long-term administra-
tion of endothelin receptor antagonist improves coronary
endothelial function in patients with early atherosclerosis.
Circulation 122:958–966
Rodriguez MR, Soria LR, Ventimiglia MS et al (2013) Endothelin-1
and -3 induce choleresis in the rat through ETB receptors
coupled to nitric oxide and vagovagal reflexes. Clin Sci
125:521–532
Rodriguez-Pascual F, Redondo-Horcajo M, Lamas S (2003) Func-
tional cooperation between Smad proteins and activator protein-
1 regulates transforming growth factor-b-mediated induction of
endothelin- 1 expression. Circ Res 92:1288–1295
Ross EA (2012) Congestive renal failure: the pathophysiology and
treatment of renal venous hypertension. J Card Fail 18:930–938
Roth J, De Souza GE (2001) Fever induction pathways: evidence
from responses to systemic or local cytokine formation. Braz J
Med Biol Res 34:301–314
Rullman E, Gustafsson T, Ahlborg G (2010) The impact of the
endothelin type A receptor on regional endothelin-1 turnover, in
particular renal endothelin-1 release, in humans. J Appl Physiol
108:1625–1630
Ryu SM, Kim HJ, Cho KR et al (2009) Myocardial protective effect
of tezosentan, an endothelin receptor antagonist, for ischemia-
reperfusion injury in experimental heart failure models. J Korean
Med Sci 24:782–788
Sagy M, Al-Qaqaa Y, Kim P (2013) Definitions and pathophysiology
of sepsis. Curr Probl Pediatr Adolesc Health Care 43:260–263
Sa´nchez-Etayo G, Borrat X, Escobar B et al (2012) Effect of intra-
abdominal pressure on hepatic microcirculation: implications of
the endothelin-1 receptor. J Dig Dis 13:478–485
Scalera F, Dittrich R, Beckmann MW et al (2002) Effect of
endothelin-1 on intracellular glutathione and lipid peroxide
availability and on the secretion of vasoactive substances by
human umbilical vein endothelial cells. Eur J Clin Invest
32:556–562
Schelman WR, Liu G, Wilding G et al (2011) A phase I study of
zibotentan (ZD4054) in patients with metastatic, castrate-resis-
tant prostate cancer. Invest New Drugs 29:118–125
Schuuring MJ, Vis JC, van Dijk AP et al (2013) Impact of bosentan
on exercise capacity in adults after the Fontan procedure: a
randomized controlled trial. Eur J Heart Fail 15:690–698
Sengul O, Ferah I, Polat B et al (2013) Blockade of endothelin
receptors with bosentan limits ischaemia/reperfusion-induced
injury in rat ovaries. Eur J Obstet Gynecol Reprod Biol
170:458–463
Shao D, Park JE, Wort SJ (2011) The role of endothelin-1 in the
pathogenesis of pulmonary arterial hypertension. Pharmacol Res
63:504–511
Shen J, Pan JW, Fan ZX et al (2013) Dissociation of vasospasm-
related morbidity and outcomes in patients with aneurysmal
subarachnoid hemorrhage treated with clazosentan: a meta-
analysis of randomized controlled trials. J Neurosurg
119:180–189
Sidharta PN, van Giersbergen PL, Dingemanse J (2013) Safety,
tolerability, pharmacokinetics, and pharmacodynamics of ma-
citentan, an endothelin receptor antagonist, in an ascending
multiple-dose study in healthy subjects. J Clin Pharmacol
53:1131–1138
Simeone SM, Li MW, Paradis P et al (2011) Vascular gene expression
in mice overexpressing human endothelin-1 targeted to the
endothelium. Physiol Genomics 43:148–160
Singh G, Sharma B, Jaggi AS et al (2014) Efficacy of bosentan, a
dual ETA and ETB endothelin receptor antagonist, in
experimental diabetes induced vascular endothelial dysfunc-
tion and associated dementia in rats. Pharmacol Biochem
Behav 124C:27–35
Sugiura M, Inagami T, Kon V (1989) Endotoxin stimulates endothe-
lin-release in vivo and in vitro as determined by
radioimmunoassay. Biochem Biophys Res Commun
161:1220–1227
Arch. Immunol. Ther. Exp. (2015) 63:41–52 51
123
Takatsuki S, Rosenzweig EB, Zuckerman W et al (2013) Clinical
safety, pharmacokinetics, and efficacy of ambrisentan therapy in
children with pulmonary arterial hypertension. Pediatr Pulmonol
48:27–34
Thakali K, Demel SL, Fink GD et al (2005) Endothelin-1-induced
contraction in veins is independent of hydrogen peroxide. Am J
Physiol Heart Circ Physiol 289:H1115–H1122
Thakkar SG, Choueiri TK, Garcia JA (2006) Endothelin receptor
antagonists: rationale, clinical development, and role in prostate
cancer therapeutics. Curr Oncol Rep 8:108–113
Tirapelli CR, Legros E, Brochu I et al (2008) Chronic ethanol intake
modulates vascular levels of endothelin-1 receptor and enhances
the pressor response to endothelin-1 in anaesthetized rats. Br J
Pharmacol 154:971–981
Tonari M, Kurimoto T, Horie T et al (2012) Blocking endothelin-B
receptors rescues retinal ganglion cells from optic nerve injury
through suppression of neuroinflammation. Invest Ophthalmol
Vis Sci 53:3490–3500
Vaneˆckova´ I, Kramer HJ, Ba¨cker A et al (2005) Early endothelin-A
receptor blockade decreases blood pressure and ameliorates end-
organ damage in homozygous Ren-2 rats. Hypertension
46:969–974
Virdis A, Schiffrin EL (2003) Vascular inflammation: a role in
vascular disease in hypertension? Curr Opin Nephrol Hypertens
12:181–187
Viswanatha Swamy AH, Wangikar U, Koti BC et al (2011)
Cardioprotective effect of ascorbic acid on doxorubicin-induced
myocardial toxicity in rats. Indian J Pharmacol 43:507–511
Wanecek M, Weitzberg E, Rudehill A et al (2000) The endothelin
system in septic and endotoxin shock. Eur J Pharmacol 407:1–15
Wang RF, Podos SM, Serle JB et al (2011) Effect of SPP 301, an
endothelin antagonist, on intraocular pressure in glaucomatous
monkey eyes. Curr Eye Res 36:41–46
Wedgwood S, Dettman RW, Black SM (2001) ET-1 stimulates
pulmonary arterial smooth muscle cell proliferation via
induction of reactive oxygen species. Am J Physiol Lung Cell
Mol Physiol 281:L1058–L1067
Wong F, Moore K, Dingemanse J et al (2008) Lack of renal
improvement with nonselective endothelin antagonism with
tezosentan in type 2 hepatorenal syndrome. Hepatology
47:160–168
Wort SJ, Ito M, Chou PC et al (2009) Synergistic induction of
endothelin-1 by tumor necrosis factor alpha and interferon c is
due to enhanced NF-jB binding and histone acetylation at
specific jB sites. J Biol Chem 284:24297–24305
Xie K, Liu L, Yu Y et al (2014) Hydrogen gas presents a promising
therapeutic strategy for sepsis. Biomed Res Int 2014:807635
Xu H, Lin L, Yuan WJ (2003) Antiarrhythmic effect of endothelin-A
receptor antagonist on acute ischemic arrhythmia in isolated rat
heart. Acta Pharmacol Sin 24:37–44
Yamashita J, Ogawa M, Nomura K et al (1993) Interleukin 6
stimulates the production of immunoreactive endothelin 1 in
human breast cancer cells. Cancer Res 53:464–467
Yanagisawa M, Kurihara H, Kimura S et al (1988) A novel potent
vasoconstrictor peptide produced by vascular endothelial cells.
Nature 332:411–415
Yeager ME, Belchenko DD, Nguyen CM et al (2012) Endothelin-1,
the unfolded protein response, and persistent inflammation: role
of pulmonary artery smooth muscle cells. Am J Respir Cell Mol
Biol 46:14–22
Yoon MH, Reriani M, Mario G et al (2013) Long-term endothelin
receptor antagonism attenuates coronary plaque progression in
patients with early atherosclerosis. Int J Cardiol 168:1316–1321
Yoshizumi M, Kurihara H, Sugiyama T et al (1989) Hemodynamic
shear stress stimulates endothelin production by cultured endo-
thelial cells. Biochem Biophys Res Commun 161:859–864
Zhang Y, Zhao C, He W et al (2014) Discovery and evaluation of
asymmetrical monocarbonyl analogs of curcumin as anti-
inflammatory agents. Drug Des Devel Ther 8:373–382
52 Arch. Immunol. Ther. Exp. (2015) 63:41–52
123
